Vertex Pharma stock trades 0.88 percent below Xetra close of EUR 459.65 in weekend trading
Published on 10/10/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Vertex Pharma traded at EUR 455.60 in weekend trading at Lang & Schwarz on October 10, 2026.
- The price was 0.88 percent below the EUR 459.65 close at Lang & Schwarz on October 9, 2026.
- Vertex reported interim ALYFTREK data from 48 children and scheduled its third-quarter results for November 2, 2026.
Market context: Market report Nasdaq Composite.
Vertex Pharma stock traded at EUR 455.60 in weekend trading at Lang & Schwarz at 10:43 a.m. CEST on October 10, 2026, down 0.88 percent versus the close of EUR 459.65 at Lang & Schwarz on October 9, 2026.
The week in figures
The latest Lang & Schwarz price was EUR 455.60, compared with the EUR 459.65 close of the last Xetra trading day on October 9, 2026. The reference move was minus 0.88 percent. Bid and ask prices were EUR 454.70 and EUR 456.50, respectively.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.
Chronology of the week
October 9, 2026: Vertex Pharmaceuticals Incorporated announced interim ALYFTREK data from 48 children aged 2 to 5 years. Eighteen children, or 37.50 percent, discontinued pancreatic enzyme replacement therapy for a mean duration of 8.60 weeks, according to the Vertex Pharmaceuticals newsroom.
October 7, 2026: Vertex announced that it will report third-quarter 2026 financial results on November 2, 2026, after the financial markets close, in a company release.
Dates of the coming week
The next substantiated company date is November 2, 2026, when Vertex Pharmaceuticals Incorporated plans to report third-quarter 2026 results after the market close and hold its conference call at 4:30 p.m. ET.
